InvestorsHub Logo
Followers 87
Posts 33372
Boards Moderated 87
Alias Born 03/22/2005

Re: None

Wednesday, 03/17/2021 3:07:44 AM

Wednesday, March 17, 2021 3:07:44 AM

Post# of 759
>>> Surface Oncology, Inc. (SURF), a clinical-stage immuno-oncology company, engages in the development of cancer therapies in the United States. The company develops antibodies, including SRF231 inhibiting CD47; NZV930 inhibiting CD73; SRF617 inhibiting CD39; SRF388 targeting interleukin 27; SRF813 targeting CD112R; and SRF114 targeting the chemokine receptor CCR8. It also develops various earlier stage programs that targets other critical components of the tumor microenvironment, including regulatory T cells. The company has a strategic collaboration agreement with Novartis Institutes for Biomedical Research, Inc. for the development of cancer therapies; and GlaxoSmithKline to develop and commercialize specified antibodies, including SRF813 targeting CD112R. Surface Oncology, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

<<<


Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.